Final Program
4njPuP
4njPuP
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
214 MONDAY • MAY 16<br />
B86<br />
BASIC • CLINICAL • TRANSLATIONAL<br />
SCIENTIFIC SYMPOSIUM<br />
CME Credits Available: 2.0<br />
IMMUNOTHERAPY FOR LUNG CANCER: POWER<br />
TO THE HOST<br />
Assemblies on Thoracic Oncology; Allergy, Immunology and Inflammation<br />
2:15 p.m. - 4:15 p.m. MOSCONE CENTER<br />
Room 303/305 (South Building, Esplanade Level)<br />
Target Audience<br />
Providers of lung health, pulmonary oncologists and/or practitioners of all health<br />
specialties participating in tumor boards, researchers in cancer and immunology,<br />
nursing (all subspecialties), pulmonary trainees.<br />
Objectives<br />
At the conclusion of this session, the participant will be able to:<br />
• learn and apply new FDA approved agents for immunotherapy in lung cancer to<br />
correct subsets with the disease;<br />
• understand new strategies to manage the care of advanced-stage lung cancer<br />
patients;<br />
• improve current treatments through translational development and improve basic<br />
biological understanding of the immune system in lung cancer.<br />
This scientific symposium will focus on both existing and promising translational<br />
approaches to immunotherapy in the treatment of lung cancer. It will cover both<br />
biological mechanisms that mediate baseline immunosuppression in lung cancer along<br />
with rational and state of the art use of existing (FDA approved) and highly promising<br />
approaches to achieve immune-mediated regression and/or cures in advanced-stage<br />
lung cancer. Developments in adjuvant immune-checkpoint and whole cell-based as<br />
well as vaccine approaches together with basic science concepts in immunologic<br />
signaling and host microenvironment will also be included. The science will cover novel<br />
genetic and epigenetic concepts as well.<br />
Chairing: M.M. Fuster, MD, San Diego, CA<br />
Z.G. Fridlender, MD, Jerusalem, Israel<br />
2:15 State of PD1/PDL1 Targeting in Lung Cancer<br />
R.M. Huber, MD, PhD, Munich, Germany<br />
2:35 Immunity Biomarkers and the Mutational Landscape in Lung<br />
Cancer<br />
E.B. Garon, MD, Los Angeles, CA<br />
2:55 Novel Immune Checkpoint Blockade Approaches<br />
S. Patel, MD, La Jolla, CA<br />
3:15 Immunosuppression and the Tumor Microenvironment<br />
A.M. Houghton, MD, Seattle, WA<br />
3:35 Treating Thoracic Malignancies with Adoptive T Cell Transfer:<br />
Successes and Challenges<br />
S. Albelda, MD, Philadelphia, PA<br />
3:55 Immune Considerations and Therapy for Mesothelioma<br />
D.H. Sterman, MD, New York, NY<br />
This session and the International Conference are supported by an educational grant from<br />
AstraZeneca LP.<br />
All CME sessions have been planned and implemented in accordance with the Essential<br />
Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME)<br />
and are free of the control of commercial interests.<br />
B87<br />
BASIC • CLINICAL • TRANSLATIONAL<br />
SCIENTIFIC SYMPOSIUM<br />
CME Credits Available: 2.0<br />
BEYOND BMPR2: EMERGING ROLES OF DNA<br />
DAMAGE AND SOMATIC MUTATION IN<br />
PULMONARY ARTERIAL HYPERTENSION<br />
Assemblies on Pulmonary Circulation; Respiratory Cell and Molecular<br />
Biology<br />
2:15 p.m. - 4:15 p.m. MOSCONE CENTER<br />
Target Audience<br />
Basic research scientists and clinician scientists.<br />
Room 3007/3009 (West Building, Level 3)<br />
Objectives<br />
At the conclusion of this session, the participant will be able to:<br />
• learn new findings about how BMPR2 mutations impact the redox state and<br />
signaling environment of pulmonary arterial cells and impose a mutagenic<br />
risk on the mitochondrial genome;<br />
• learn new concepts about mitochondria retrograde signaling to the nucleus<br />
and how this process is impacted by mtDNA mutations;<br />
• learn new concepts about DNA damage and somatic mutation in pulmonary<br />
arterial hypertension.<br />
Like cancer, pulmonary artery hypertension (PAH) has a prominent genetic<br />
component. For example, in familial as well as a proportion of sporadic PAH,<br />
germline mutations in the BMPR2 gene are a documented risk factor for the<br />
disease. In addition, hypertensive pulmonary cells also display an array of<br />
somatic mutations, but little is known about mechanisms of their formation, their<br />
functional consequences, and the potential that such somatic mutations could<br />
serve as diagnostic or prognostic biomarkers or therapeutic targets.<br />
Accordingly, the goal of this Scientific Symposium is to highlight emerging roles<br />
of DNA damage and somatic mutation in pulmonary arterial hypertension.<br />
Chairing: M. Aldred, PhD, Cleveland, OH<br />
M.N. Gillespie, PhD, Mobile, AL<br />
2:15 The Link Between BMPR2, Mitochondrial Dysfunction and<br />
Vulnerability to DNA Damage in Pulmonary Hypertension<br />
M. Rabinovitch, MD, Stanford, CA<br />
2:35 Mitochondrial DNA Mutations and Their Impact on Nuclear<br />
Gene Expression<br />
D. Wallace, PhD, Philadelphia, PA<br />
2:55 Transcriptional Regulation in Hypoxic Cells by Controlled DNA<br />
“Damage” and Repair<br />
M.N. Gillespie, PhD, Mobile, AL<br />
3:15 The DNA Damage Response in PAH<br />
S. Bonnet, PhD, Quebec, Canada<br />
3:35 DNA Damage and Repair and Somatic Mutation in PAH<br />
M. Aldred, PhD, Cleveland, OH<br />
3:55 The Cancer Paradigm for Pulmonary Arterial Hypertension: An<br />
Update<br />
M.J.C. Humbert, MD, PhD, Le Kremlin Bicetre, France<br />
ATS 2016 • San Francisco